Hybridon/Medtronic
This article was originally published in The Gray Sheet
Executive Summary
Medtronic makes a $4 mil. equity investment in the Worcester, Massachusetts-based firm as part of a research collaboration pact to develop antisense oligonucleotide compounds and delivery systems for the treatment of Alzheimer's disease. Under the terms of the deal, Hybridon will develop the compounds and perform initial studies. Depending on the outcome, the compounds could be adapted for use with Medtronic's SynchroMed implantable drug infusion system.